FarmaKology Newsletter - Issue #13
GFBiochemicals brings biobased levulinic acid to market through technology innovation. Founded in 2008, GFBiochemicals is the first company to produce levulinic acid at commercial scale directly from biomass. With proprietary technology and a commercial-scale plant in Caserta, Italy, GFBiochemicals’ levulinic acid is the platform chemical with significant potential to replace petroleum-based products in chemicals and biofuels.
A new protocol implemented to treat patients with sepsis reduced the time that they were on broad-spectrum antibiotics, decreased their length of stay and saved a hospital in Pennsylvania over $300,000 in 4 months, according to findings presented at the conference for the Association for Professionals in Infection Control Epidemiology.
DermBiont, a clinical stage therapeutics company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases has closed an $8M Series A.
Ricoh Company, Ltd., today announced it has entered into a strategic business partnership with Elixirgen Scientific, Inc., to develop innovative biomedical products and services that support drug discovery based on cell differentiation*1 technology.
Boehringer Ingelheim and the University of Dundee have highlighted the success of the PROTAC drug discovery program, and thus extended their ongoing anti-cancer alliance.